Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.